SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:research.chalmers.se:d726e1bb-9798-4cff-82b0-36405d50718b"
 

Sökning: onr:"swepub:oai:research.chalmers.se:d726e1bb-9798-4cff-82b0-36405d50718b" > Plasma and Urine Fr...

  • Gatto, Francesco,1987Karolinska Institutet (författare)

Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:research.chalmers.se:d726e1bb-9798-4cff-82b0-36405d50718b
  • https://doi.org/10.1200/PO.22.00361DOI
  • https://research.chalmers.se/publication/539546URI
  • https://gup.ub.gu.se/publication/334152URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:154582281URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • PURPOSENo liquid biomarkers are approved in metastatic renal cell carcinoma (mRCC) despite the need to predict and monitor response noninvasively to tailor treatment choices. Urine and plasma free glycosaminoglycan profiles (GAGomes) are promising metabolic biomarkers in mRCC. The objective of this study was to explore if GAGomes could predict and monitor response in mRCC.PATIENTS AND METHODSWe enrolled a single-center prospective cohort of patients with mRCC elected for first-line therapy (ClinicalTrials.gov identifier: NCT02732665) plus three retrospective cohorts (ClinicalTrials.gov identifiers: NCT00715442 and NCT00126594) for external validation. Response was dichotomized as progressive disease (PD) versus non-PD every 8-12 weeks. GAGomes were measured at treatment start, after 6-8 weeks, and every third month in a blinded laboratory. We correlated GAGomes with response and developed scores to classify PD versus non-PD, which were used to predict response at treatment start or after 6-8 weeks.RESULTSFifty patients with mRCC were prospectively included, and all received tyrosine kinase inhibitors (TKIs). PD correlated with alterations in 40% of GAGome features. We developed plasma, urine, and combined glycosaminoglycan progression scores that monitored PD at each response evaluation visit with the area under the receiving operating characteristic curve (AUC) of 0.93, 0.97, and 0.98, respectively. For internal validation, the scores predicted PD at treatment start with the AUC of 0.66, 0.68, and 0.74 and after 6-8 weeks with the AUC of 0.76, 0.66, and 0.75. For external validation, 70 patients with mRCC were retrospectively included and all received TKI-containing regimens. The plasma score predicted PD at treatment start with the AUC of 0.90 and at 6-8 weeks with the AUC of 0.89. The pooled sensitivity and specificity were 58% and 79% at treatment start. Limitations include the exploratory study design.CONCLUSIONGAGomes changed in association with mRCC response to TKIs and may provide biologic insights into mRCC mechanisms of response.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bratulic, Sinisa,1981Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)bratulic (författare)
  • Jonasch, Eric (författare)
  • Limeta, Angelo,1996Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)angelol (författare)
  • Maccari, F.Universita Degli Studi Di Modena E Reggio Emilia,University of Modena and Reggio Emilia (författare)
  • Galeotti, FabioUniversita Degli Studi Di Modena E Reggio Emilia,University of Modena and Reggio Emilia (författare)
  • Volpi, NicolaUniversita Degli Studi Di Modena E Reggio Emilia,University of Modena and Reggio Emilia (författare)
  • Lundstam, Sven,1944Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Urology,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xlusvl (författare)
  • Nielsen, Jens B,1962Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)nielsenj (författare)
  • Stierner, Ulrika,1952Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xstiul (författare)
  • Karolinska InstitutetChalmers tekniska högskola (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:JCO PRECISION ONCOLOGY72473-4284

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy